Eli Lilly's Prevail strikes potential billion-dollar AAV capsids deal with Sangamo for neurological diseases
Eli Lilly’s Prevail Therapeutics has expanded again into neurological targets thanks to a potential billion-dollar deal with Sangamo Therapeutics. The pair …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
